Search results
Showing 76 to 90 of 103 results for rituximab
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]
Discontinued [GID-TAG278]
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
Discontinued [GID-TAG321]
Awaiting development [GID-TA11488] Expected publication date: TBC
Discontinued [GID-TA10109]
After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.
Any explanatory notes(if applicable) Why this is important:- Before rituximab, it was accepted that high-grade transformation of...
Idelalisib for treating refractory follicular lymphoma (TA604)
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 243.